Tuesday, September 22, 2020 11:07:55 PM
misiu143,
I appreciate your post. Yes...Guilty! I have been pushing for the long-hauler trial for a few reasons:
1. It appears Leronlimab (as per the M-M) starts positively making changes by the third day. While changes do not = instant cure, it does mean the various indicators (CD-4,CD-8, IL-6, etc.) are coming back into balance. ...And the cytokine storm begins to subside.
2. While everyone is chasing the vaccine/immediate treatment "golden fleece," Leronlimab would be virtually alone in going after the "long-hauler" market.
3. It has been hard getting "traction" in the (covid treatment/cure) crowded field of applicants. LL gets lost in the shuffle. Meanwhile, there are already frustrated groups of organized "long-haulers" that would provide potential motivated pressure for approval.
4. This would not be a Looooooong trial. It either works (in 3, 7, 14, or 28 days ?) or doesn't. Plus, it would be easier to populate such a trial as there are many reaching out for relief.
5. This is a very significant market. I wonder if there is any count as to what percentage of the "recovered" have varying degrees of the "long-hauler" syndrome? I've seen estimates ranging from one third to seven eighth's of "recovered" exhibit varying degrees of "long-hauler" syndrome. That's talking a market of millions in the USA alone...and elsewhere?
6. Many "long-haulers" no longer have any remnants of Covid19, in fact some never seemed to manifest the disease. For that reason many if not all of their expenses must be covered by insurance or are totally "out-of-pocket." These people (and families) are desperate.
But...Rockleo's post really "rocked my boat. " I do not wish to jeopardize the success of Leronlimab. This is why, Misiu143, I really appreciate your post. It seems imperative a "long-hauler" trial must include entry parameters noting the previous health of the patients. Rockleo's point is well taken, many of these people may have profound "pre-existing conditions" and LL is not "Jesus curing the afflicted." LL may be able to help with the immunological aftermath of Covid19 but will not help the lame to walk or the blind to see. For that reason - applicant screening to rule out confounding pre-existing conditions would be a key for acceptance.
So ...THANK YOU.. now for the Rock...
Rockleo - what do you think about Misiu143's suggestion?
I appreciate your post. Yes...Guilty! I have been pushing for the long-hauler trial for a few reasons:
1. It appears Leronlimab (as per the M-M) starts positively making changes by the third day. While changes do not = instant cure, it does mean the various indicators (CD-4,CD-8, IL-6, etc.) are coming back into balance. ...And the cytokine storm begins to subside.
2. While everyone is chasing the vaccine/immediate treatment "golden fleece," Leronlimab would be virtually alone in going after the "long-hauler" market.
3. It has been hard getting "traction" in the (covid treatment/cure) crowded field of applicants. LL gets lost in the shuffle. Meanwhile, there are already frustrated groups of organized "long-haulers" that would provide potential motivated pressure for approval.
4. This would not be a Looooooong trial. It either works (in 3, 7, 14, or 28 days ?) or doesn't. Plus, it would be easier to populate such a trial as there are many reaching out for relief.
5. This is a very significant market. I wonder if there is any count as to what percentage of the "recovered" have varying degrees of the "long-hauler" syndrome? I've seen estimates ranging from one third to seven eighth's of "recovered" exhibit varying degrees of "long-hauler" syndrome. That's talking a market of millions in the USA alone...and elsewhere?
6. Many "long-haulers" no longer have any remnants of Covid19, in fact some never seemed to manifest the disease. For that reason many if not all of their expenses must be covered by insurance or are totally "out-of-pocket." These people (and families) are desperate.
But...Rockleo's post really "rocked my boat. " I do not wish to jeopardize the success of Leronlimab. This is why, Misiu143, I really appreciate your post. It seems imperative a "long-hauler" trial must include entry parameters noting the previous health of the patients. Rockleo's point is well taken, many of these people may have profound "pre-existing conditions" and LL is not "Jesus curing the afflicted." LL may be able to help with the immunological aftermath of Covid19 but will not help the lame to walk or the blind to see. For that reason - applicant screening to rule out confounding pre-existing conditions would be a key for acceptance.
So ...THANK YOU.. now for the Rock...
Rockleo - what do you think about Misiu143's suggestion?
Recent CYDY News
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
